Development of a new benzodiazepine hypnotics withdrawal symptom scale

  • Mina Kobayashi
  • Isa Okajima
  • Hajime Narisawa
  • Takashi Kikuchi
  • Kentaro Matsui
  • Ken Inada
  • Jun Ishigooka
  • Yuichi Inoue
Original Article
  • 2 Downloads

Abstract

For prevention and early detection of dependence on hypnotics such as benzodiazepines (BZDs) or its agonists, a withdrawal symptom scale specialized for this kind of drug has long been sought. In this study, the benzodiazepine hypnotics withdrawal symptom scale (BHWSS) was developed using item response theory (IRT). This study enrolled 121 chronic insomnia patients (mean age 46.1 ± 15.6 years) who had been treated with hypnotics for 3 or more months. The patients were asked to fill a questionnaire that was developed by selecting questions from Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) and Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) on the basis of the symptoms triggered by reduction or abrupt cessation of the intake of hypnotics. A factor analysis was performed to verify the assumption that the new scale had one dimension. We drew item response category characteristic curves, following the IRT. Besides statistical considerations, clinical implications were also incorporated to select the 12 items used to construct the BHWSS questionnaire. Using the analyses based on IRT, 6 items each were selected from BWSQ and CIWA-B. The cumulative proportion of contribution of the first factor, obtained by factor analysis, was found to be 0.36. Cronbach’s α coefficient and McDonald’s ω coefficient were calculated to be 0.86 and 0.87, respectively. The total score of 12 items increased monotonically with the increasing level of withdrawal symptoms. The BHWSS could potentially become a practical tool for estimating the degree of BZD withdrawal symptoms.

Keywords

Insomnia Benzodiazepine and benzodiazepine receptor agonist hypnotics Withdrawal symptom Self-checked questionnaire Item response theory Factor analysis 

Notes

Acknowledgements

For creating of the new scale reported in this study, we obtained permission from Peter Tyrer (BWSQ) and Edward M. Sellers (CIWA-B) to use the questionnaire scales. The authors would like to offer special thanks to Shyun Nakajima, staff of Teikyo University, and Moeko Ochi, staff of Soshin Mental Care Clinic for recruitment and collecting data. We would like to thank Editage (http://www.editage.jp) for English language editing.

Compliance with ethical standards

Conflict of interest

Takashi Kikuchi, a member of Translational Research Information Center, was consulted for statistical analysis but was not involved in writing the manuscript or collecting data. Other authors have no conflict of interest in this study.

Ethical approval

All the procedures undertaken to perform experiments involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all the participants included in this study.

References

  1. 1.
    American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien: American Academy of Sleep Medicine; 2014.Google Scholar
  2. 2.
    Ohayon MM, Partinen M. Insomnia and global sleep dissatisfaction in Finland. J Sleep Res. 2002;11:339–46.CrossRefPubMedGoogle Scholar
  3. 3.
    Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42:225–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32:491–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Staner L. Comorbidity of insomnia and depression. Sleep Med Rev. 2010;14:35–46.CrossRefPubMedGoogle Scholar
  6. 6.
    Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, Lombardo C, Riemann D. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135:10–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, Buysse DJ. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159:5–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Okajima I, Komada Y, Inoue Y. A meta-analysis on the treatment effectiveness of cognitive behavioral therapy for primary insomnia. Sleep Biol Rhythms. 2011;9:24–34.CrossRefGoogle Scholar
  9. 9.
    Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307–49.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Murakoshi A, Takaesu Y, Komada Y, Ishikawa J, Inoue Y. Prevalence and associated factors of hypnotics dependence among Japanese outpatients with psychiatric disorders. Psychiatry Res. 2015; 230:958–963.Google Scholar
  11. 11.
    Hallstron C. Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry. 1981;16:235–44.CrossRefGoogle Scholar
  12. 12.
    Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986;315:854–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18:37–48.CrossRefPubMedGoogle Scholar
  14. 14.
    de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines: more “behavioural” addiction than dependence. Psychopharmacology. 2003;167:297–303.CrossRefPubMedGoogle Scholar
  15. 15.
    Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994;48:25–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2009;57:761–89.CrossRefGoogle Scholar
  17. 17.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Association, Arlington; 2013.Google Scholar
  18. 18.
    Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77:295–301.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf. 2014;13:919–34.CrossRefGoogle Scholar
  20. 20.
    Tyrer P, Murphy S, Riley P. The benzodiazepine withdrawal symptom questionnaire. J Affect Disord. 1990;19:53–61.CrossRefPubMedGoogle Scholar
  21. 21.
    Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol. 1989;9:412–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Christine DeMars. Item response theory (understanding statistics). Oxford University Press, New York; 2010 ISBN-13:978-0195377033.Google Scholar
  23. 23.
    Lähteenmäki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä SL. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77:975–85.CrossRefGoogle Scholar
  24. 24.
    Lichstein KL, Nau SD, Wilson NM, Aguillard RN, Lester KW, Bush AJ, McCrae CS. Psychological treatment of hypnotic-dependent insomnia in a primarily older adult sample. Behav Res Ther. 2013;51:787–96.CrossRefPubMedGoogle Scholar
  25. 25.
    Roehrs TA1, Randall S, Harris E, Maan R, Roth T. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol. 2012;26:1088–95.CrossRefPubMedGoogle Scholar
  26. 26.
    Krystal AD1, Lankford A, Durrence HH, Ludington E, Jochelson P, Rogowski R, Roth T. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34:1433–42.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:51.  https://doi.org/10.1186/1741-7015-8-51.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Toyoda H. Item response theory—case example.In 項目反応理論[事例編]. 7th ed. Tokyo: Asakura Publishing Co., Ltd; 2014.Google Scholar
  29. 29.
    McDonald RP. Generalizability in factorable domains: “domain validity and generalizability" 1. Educ Psychol Meas. 1978;38:75–9.CrossRefGoogle Scholar
  30. 30.
    Couvée JE1, Zitman FG. The Benzodiazepine Withdrawal Symptom Questionnaire: psychometric evaluation during a discontinuation program in depressed chronic benzodiazepine users in general practice. Addiction. 2002;97:337–45.CrossRefGoogle Scholar
  31. 31.
    Tolbert D, Harris SI, Bekersky I, Lee D, Isojarvi J. Withdrawal-related adverse events from clinical trials of clobazam in Lennox–Gastaut syndrome. Epilepsy Behav. 2014;37:11–5.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Sleep Research 2018

Authors and Affiliations

  • Mina Kobayashi
    • 1
    • 2
  • Isa Okajima
    • 1
    • 3
  • Hajime Narisawa
    • 1
  • Takashi Kikuchi
    • 4
  • Kentaro Matsui
    • 1
    • 5
  • Ken Inada
    • 5
  • Jun Ishigooka
    • 6
  • Yuichi Inoue
    • 1
    • 2
    • 7
  1. 1.Japan Somnology CenterInstitute of NeuropsychiatryTokyoJapan
  2. 2.Foundation of Sleep and Health ScienceTokyoJapan
  3. 3.Faculty of Human SciencesWaseda UniversityTokorozawaJapan
  4. 4.Translational Research Information CenterKobeJapan
  5. 5.Department of PsychiatryTokyo Women’s Medical UniversityTokyoJapan
  6. 6.Institute of CNS PharmacologyTokyoJapan
  7. 7.Department of SomnologyTokyo Medical UniversityTokyoJapan

Personalised recommendations